Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAge Labs, Inc.BIOA · Entity 5569 | Chief Medical Officer | April 01, 2026 | April 03, 2026 |
| Viridian Therapeutics, Inc.\DEMGEN · Entity 4316 | EVP, Research & Development | February 06, 2019 | February 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAge Labs, Inc.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-04-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-04-01 · Exercise / conversion · Acquired 5,437 · Balance 5,437 F1: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Row 2 · 2026-04-01 · Exercise / conversion · Acquired 3,383 · Balance 8,820 F1: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Row 3 · 2026-04-01 · Sale · Disposed 8,820 · Balance 0 F1: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2030-06-30 | Direct | 0 |
Reported balance
After 2026-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-01 · Exercise / conversion · Disposed 5,437 · Balance 0 F1: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F2: This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.57 · Expires 2032-05-28 | Direct | 0 |
Reported balance
After 2026-04-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-01 · Exercise / conversion · Disposed 3,383 · Balance 0 F1: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F3: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.
F2: This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.
F3: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Viridian Therapeutics, Inc.\DE
Report date February 06, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2029-02-05 | Direct | 87,000 |
Reported balance
After 2019-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-06 · Grant · Acquired 87,000 · Balance 87,000 F1: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on May 7, 2019 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on May 7, 2019 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 3, 2026 20:07 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,383 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001210905-26-000011 · form4-04032026_080407.xml · derivative · entry 5 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,383 shares Expires 2032-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F3 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:07 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,437 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001210905-26-000011 · form4-04032026_080407.xml · derivative · entry 4 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,437 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F2 · derivative.exercise_date: This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:07 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 8,820 | $17.81 | $157,084.20 |
DisclosureSEC source: 0001210905-26-000011 · form4-04032026_080407.xml · nonDerivative · entry 3 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:07 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 3,383 | $6.57 | $22,226.31 |
DisclosureSEC source: 0001210905-26-000011 · form4-04032026_080407.xml · nonDerivative · entry 2 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:07 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 5,437 | $4.11 | $22,346.07 |
DisclosureSEC source: 0001210905-26-000011 · form4-04032026_080407.xml · nonDerivative · entry 1 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:46 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001210905-26-000009 · form4-03032026_090341.xml · derivative · entry 5 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,383 Underlying: Common Stock · 2,000 shares Expires 2032-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F3 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:46 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,433 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001210905-26-000009 · form4-03032026_090341.xml · derivative · entry 4 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,437 Underlying: Common Stock · 5,433 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F2 · derivative.exercise_date: This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:46 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 7,433 | $20.30 | $150,889.90 |
DisclosureSEC source: 0001210905-26-000009 · form4-03032026_090341.xml · nonDerivative · entry 3 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:46 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 2,000 | $6.57 | $13,140.00 |
DisclosureSEC source: 0001210905-26-000009 · form4-03032026_090341.xml · nonDerivative · entry 2 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:46 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 5,433 | $4.11 | $22,329.63 |
DisclosureSEC source: 0001210905-26-000009 · form4-03032026_090341.xml · nonDerivative · entry 1 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:42 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001210905-26-000007 · form4-02192026_090237.xml · derivative · entry 1 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:26 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001210905-26-000005 · form4-02032026_090207.xml · derivative · entry 5 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,383 Underlying: Common Stock · 2,000 shares Expires 2032-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F3 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:26 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,433 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001210905-26-000005 · form4-02032026_090207.xml · derivative · entry 4 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,870 Underlying: Common Stock · 5,433 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F2 · derivative.exercise_date: This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:26 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 7,433 | $18.75 | $139,368.75 |
DisclosureSEC source: 0001210905-26-000005 · form4-02032026_090207.xml · nonDerivative · entry 3 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:26 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 2,000 | $6.57 | $13,140.00 |
DisclosureSEC source: 0001210905-26-000005 · form4-02032026_090207.xml · nonDerivative · entry 2 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:26 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 5,433 | $4.11 | $22,329.63 |
DisclosureSEC source: 0001210905-26-000005 · form4-02032026_090207.xml · nonDerivative · entry 1 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:24 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001210905-26-000002 · form4-01062026_090157.xml · derivative · entry 5 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,383 Underlying: Common Stock · 2,000 shares Expires 2032-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F4 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:24 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,433 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001210905-26-000002 · form4-01062026_090157.xml · derivative · entry 4 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,303 Underlying: Common Stock · 5,433 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F3 · derivative.exercise_date: This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:24 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 7,433 | $12.85 | $95,490.26 |
DisclosureSEC source: 0001210905-26-000002 · form4-01062026_090157.xml · nonDerivative · entry 3 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.571 to $13.242 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:24 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 2,000 | $6.57 | $13,140.00 |
DisclosureSEC source: 0001210905-26-000002 · form4-01062026_090157.xml · nonDerivative · entry 2 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:24 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 5,433 | $4.11 | $22,329.63 |
DisclosureSEC source: 0001210905-26-000002 · form4-01062026_090157.xml · nonDerivative · entry 1 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:21 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001210905-25-000006 · form4-12112025_091211.xml · derivative · entry 3 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,383 Underlying: Common Stock · 18,000 shares Expires 2032-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F2 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:21 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 18,000 | $12.00 | $216,000.00 |
DisclosureSEC source: 0001210905-25-000006 · form4-12112025_091211.xml · nonDerivative · entry 2 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:21 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 18,000 | $6.57 | $118,260.00 |
DisclosureSEC source: 0001210905-25-000006 · form4-12112025_091211.xml · nonDerivative · entry 1 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:20 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 68,897 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001210905-25-000004 · form4-12052025_111241.xml · derivative · entry 3 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,736 Underlying: Common Stock · 68,897 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F3 · derivative.exercise_date: This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:20 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 68,897 | $10.19 | $701,908.86 |
DisclosureSEC source: 0001210905-25-000004 · form4-12052025_111241.xml · nonDerivative · entry 2 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.96 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:20 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 68,897 | $4.11 | $283,166.67 |
DisclosureSEC source: 0001210905-25-000004 · form4-12052025_111241.xml · nonDerivative · entry 1 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:22 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001415889-25-004867 · form4-02202025_090226.xml · derivative · entry 1 RUBIN PAUL D · CIK 0001210905 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:34 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 87,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001209191-19-008542 · doc4.xml · derivative · entry 1 RUBIN PAUL D · CIK 0001210905 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,000 Underlying: Common Stock · 87,000 shares Expires 2029-02-05 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on May 7, 2019 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
| January 31, 2018 Filed Feb 3, 2018 01:15 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-18-007264 · doc4.xml · derivative · entry 1 RUBIN PAUL D · CIK 0001210905 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2028-01-30 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). 6.25% of the shares will vest on April 30, 2018 and the remaining 93.75% of the shares will vest in equal monthly installments thereafter over 45 months, such that the stock option shall be fully vested on the four-year anniversary of the date of grant, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 01:26 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 87,500 | $0.00 Strike: $11.01 | $0.00 |
DisclosureSEC source: 0001209191-17-011781 · doc4.xml · derivative · entry 1 RUBIN PAUL D · CIK 0001210905 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2027-02-15 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares vest in 48 equal monthly installments beginning on February 16, 2017, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.